Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
about
Telemedicine in pre-hospital care: a review of telemedicine applications in the pre-hospital environmentTreating the acute stroke patient as an emergency: current practices and future opportunities.Neuroprotection and thrombolysis: combination therapy in acute ischaemic strokeCurrent perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokeUltrasound-enhanced thrombolysis with tPA-loaded echogenic liposomesAdvances in ischemic stroke treatment: neuroprotective and combination therapies.Evolution of the thrombolytic treatment window for acute ischemic stroke.Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science.Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy developmentThrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.Applications of diffusion/perfusion magnetic resonance imaging in experimental and clinical aspects of stroke.Blood glutathione S-transferase-π as a time indicator of stroke onsetPaeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses.Trends in thrombolytic use for ischemic stroke in the United States.Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.Stroke trials: what have we learned?Central nervous system agents for ischemic stroke: neuroprotection mechanismsExternal validation of the SEDAN score: The real world practice of a single center.Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection.Progesterone protects endothelial cells after cerebrovascular occlusion by decreasing MCP-1- and CXCL1-mediated macrophage infiltration.Commentary on NICE guidelines for alteplase for the treatment of acute ischaemic stroke.Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.Neuroprotective Effect of Xueshuantong for Injection (Lyophilized) in Transient and Permanent Rat Cerebral Ischemia Model.Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community HospitalsInvestigating the utility of previously developed prediction scores in acute ischemic stroke patients in the stroke beltA model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.Treatment of arterial ischemic stroke in children.Joint commission primary stroke centers utilize more rt-PA in the nationwide inpatient sample.Early stroke care in Italy--a steep way ahead: an observational study.Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated ratsIntravenous rt-PA: a tenth anniversary reflectionInfluence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.Stroke and thrombolysis in developing countries.Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.Intra-arterial stroke therapy: an assessment of demand and available work force.Can comprehensive stroke centers erase the 'weekend effect'?Implementation of an institution-wide acute stroke algorithm: Improving stroke quality metrics.Barriers to the utilization of thrombolysis for acute ischaemic stroke.
P2860
Q27023617-8A5FC21B-D026-4B77-BBF5-F320ECD3CEF1Q28196628-B14130CA-9739-4544-8EA7-D37BF9BAF62CQ28199814-8C8AE0C3-7743-41DD-929C-93E60D7878D6Q30414441-BB9B0F0B-4454-4AFC-BFEE-8D2009012890Q30480851-9D175F58-5A71-485D-A559-42884138B21FQ33278117-79954DE5-95F8-4B92-84FF-71D1587D14F1Q33688138-20D385A1-8CCE-47EE-93D2-9BEF4C0CED1DQ33734891-6D00BAD0-A330-4EC5-B7A4-00A3CD946183Q33896024-7585D157-B1DE-4F3E-AA68-0E048D00CE6FQ33938946-FC0E1FA0-0F09-4998-AEDB-7AD2FB903F18Q34111171-0E751A58-A846-4374-9365-34CC1B1D2CCFQ34175020-A0804851-5411-4B12-A034-EEE3D7CBFC5CQ34426843-1DA606FB-EB3C-456B-8726-AE4DCEAA80B3Q34482695-29B3AF63-6E95-4626-8B3E-DF72FE0A366BQ34508464-CF94AD82-6D07-4965-AFB1-9FCE3C2DA186Q34679691-103D6D8D-7583-4B36-B2DB-9933E7EFFB9DQ34695772-1F5DD47F-68A4-46E4-B31A-D4D89D09B1EBQ35137635-DF4B24DC-A25F-4294-B13E-C8C0E84CFEE2Q35651846-5B62BD3B-8680-4EB8-907E-23273F426149Q36056147-2C5C306E-CFA0-4962-9D4A-C1928DE75E40Q36101721-87707759-C0D0-43BE-97E3-29D58A19B66FQ36172914-49655165-B450-44CC-A9D1-DB6B2F9DEA32Q36283476-D8BBDEF8-427B-46A1-B98C-38F12DF7A106Q36349762-18B7EDE8-D64D-44F0-9EB7-088CF5892444Q36414557-0F301320-85F9-4CBB-89C7-5A5722A443DDQ36657709-AEFB75F1-5DE7-4F5B-93DC-C7D4FFABF349Q36685755-C30DDEB3-C1CE-4361-89E7-FD8A6F844910Q36787348-16221726-D24F-43A1-89B3-A91EF4411277Q36824775-3B2D6701-731C-4578-8323-8A2BAF2606C8Q36929399-50350EF2-773C-4510-8DA1-E38336474C52Q36955444-794861F1-6A63-4917-87E1-9D2E3B9DFF1BQ36982822-6AACDF54-7D45-400B-8FF5-88791AE8A0F7Q36993122-6D228336-6096-4343-AC6F-BA9BFDCBEE32Q37172019-FB02F231-C3F2-46AE-B82E-DB4E10FE146FQ37244517-9D405D08-146E-4E79-899A-1D529C566CD7Q37312849-D0F5EB91-1D17-4D37-AFB1-FA2D43B712AAQ37364965-08DCD7C8-876A-4A0E-9061-F3C97B34DDD1Q37464382-A10E9F3E-F23D-4925-B950-B147E7AFAEF6Q37585151-2BE98C45-7D7D-44D0-BF39-EAC96E891ACAQ37989982-A8675BC2-FAFB-4AA2-8B6A-2340880B34B1
P2860
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@ast
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@en
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@nl
type
label
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@ast
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@en
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@nl
prefLabel
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@ast
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@en
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@nl
P2093
P1433
P1476
Intravenous tissue-type plasmi ...... uston experience 1996 to 2000.
@en
P2093
Alexandrov AV
Campbell M
El-Mitwalli A
Morgenstern LB
P304
P356
10.1001/ARCHNEUR.58.12.2009
P577
2001-12-01T00:00:00Z